Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages
over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these
therapies have not been compared in an international randomized, controlled trial. Here, we
report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a
multinational, two-phase (induction and maintenance) study. We randomly assigned 370
patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or …